Comparative safety evaluation of the candidate vaginal microbicide C31G.
C31G is currently the focus of clinical trials designed to evaluate this agent as a microbicidal and spermicidal agent. In the following studies, the in vivo safety of C31G was assessed with a Swiss Webster mouse model of cervicovaginal toxicity and correlated with results from in vitro cytotoxicity experiments and published clinical observations. A single exposure of unformulated 1% C31G resulted in mild-to-moderate epithelial disruption and inflammation at 2 and 4 h postapplication. The columnar epithelium of the cervix was the primary site of damage, while no perturbation of the vaginal mucosa was observed. In contrast, application of unformulated 1.7% C31G resulted in greater levels of inflammation in the cervical epithelium at 2 h postapplication and severe epithelial disruption that persisted to 8 h postapplication. Application of a nonionic aqueous gel formulation containing 1% C31G resulted in no apparent cervicovaginal toxicity at any time point evaluated. However, formulation of 1.7% C31G did not substantially reduce the toxicity associated with unformulated C31G at that concentration. These observations correlate with findings gathered during a recent clinical trial, in which once-daily applications resulted in no adverse events in women receiving the formulation containing 1% C31G, compared to moderate-to-severe adverse events in 30% of women receiving the 1.7% C31G formulation. The Swiss Webster mouse model was able to effectively discriminate between concentrations and formulations of C31G that produced distinct clinical effects in human trials. The Swiss Webster animal model may be a highly valuable tool for preclinical evaluation of candidate vaginal microbicides.
Catalone
Bradley J
BJ
Department of Microbiology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Kish-Catalone
Tina M
TM
Neely
Elizabeth B
EB
Budgeon
Lynn R
LR
Ferguson
Mary L
ML
Stiller
Catherine
C
Miller
Shendra R
SR
Malamud
Daniel
D
Krebs
Fred C
FC
Howett
Mary K
MK
Wigdahl
Brian
B
D000282:Administration, Intravaginal; D000818:Animals; D000891:Anti-Infective Agents, Local; D001622:Betaine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000633:toxicity; D002460:Cell Line; D002584:Cervix Uteri / Q000166:cytology / Q000187:drug effects*; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage / Q000009:adverse effects* / Q000633:toxicity; D005260:Female; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D017137:Nonoxynol / Q000008:administration & dosage / Q000009:adverse effects* / Q000633:toxicity; D014621:Vagina / Q000166:cytology / Q000187:drug effects*; D014622:Vaginal Creams, Foams, and Jellies / Q000008:administration & dosage / Q000009:adverse effects / Q000633:toxicity
D000891:Anti-Infective Agents, Local; D005231:Fatty Acids, Unsaturated; D014622:Vaginal Creams, Foams, and Jellies; D017137:Nonoxynol; D001622:Betaine; C038360:C 31G